NCT01989208View on ClinicalTrials.gov

Assessing the Safety and Ability of SG1002 to Overcome Deficits in Hydrogen Sulfide in Heart Failure Patients

NACompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Heart Failure
Interventions
OTHER

SG1002

200 mg capsules will be administered BID for 7 days, then doubled to 2 capsules BID for 7 days and doubled again to 4 capsules BID for the final 7 days.

OTHER

Placebo

200 mg capsules containing placebo will be administered BID for 7 days, then doubled to 2 capsules BID for 7 days and doubled again to 4 capsules BID for the final 7 days.

Trial Locations (2)

3004

Alfred Health, Melbourne

Nucleus Network, Melbourne

All Listed Sponsors
lead

Sulfagenix Australia Pty Ltd.

INDUSTRY

NCT01989208 - Assessing the Safety and Ability of SG1002 to Overcome Deficits in Hydrogen Sulfide in Heart Failure Patients | Biotech Hunter | Biotech Hunter